Streetbeat News

Partnerships

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) announced the expansion of its commercial business through exclusive distribution agreements in the Netherlands, Belgium, Vietnam, and Switzerland for its rapid sepsis detection products. This expansion is aimed at leveraging the high demand for sepsis diagnostics in these regions, with significant patient populations affected by infections and sepsis. The agreements cover the sale of the T2Dx Instrument and various sepsis test panels, promising faster detection and treatment of sepsis-causing pathogens and antibiotic resistance genes.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 9:21 pm

TSHA

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced updates on its deprioritized pipeline programs, including the termination of an old loan and security agreement and the initiation of a new one to facilitate the transfer of IP for these programs. The new agreement extends Taysha's cash runway into 2026. The company has made progress on several programs, such as transferring rights for TSHA-120 to NINDS and TSHA-101 back to Queen's University. Taysha continues to focus on its lead TSHA-102 program for Rett syndrome while exploring partnerships for other deprioritized programs.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 9:21 pm

HROW

Harrow, Inc. (NASDAQ:HROW) has entered into an exclusive out-licensing agreement with Apotex Inc., Canada's largest pharmaceutical company, to market and distribute five branded ophthalmic pharmaceutical products in Canada. The agreement includes the marketing and distribution of VERKAZIA® and Cationorm® PLUS, as well as pursuing market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®. This partnership marks Harrow's entry into the Canadian market, aiming to enhance access and availability of these ophthalmic products to Canadian patients.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 9:20 pm

VIAV

VIAVI Solutions Inc. (VIAV) announced its VIAVI Xgig CXL Exerciser has been approved as a CXL 1.1 Gold device by the CXL Consortium, enabling it to qualify CXL devices for the CXL Integrators List. This certification is crucial for the development and testing of high-speed computing applications like AI and ML. The approval highlights VIAVI's role in the CXL validation ecosystem, with Micron acknowledging VIAVI's contribution to CXL protocol compliance. VIAVI will showcase its CXL solutions at the CXL Developers' Conference in 2024.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 9:17 pm

PEPEUSD

Robinhood Crypto EU listed Pepe (CRYPTO: PEPE) for trading, leading to a 15% rally and a one-month high of $0.000001298. Pepe's weekly gains reached 29.4% with a 43.9% increase in daily trading volume. The listing by Robinhood, which only includes 30 coins, has sparked optimism for future listings on major platforms like Coinbase and Robinhood US. Etherscan data shows an increase in Pepe holders and network activity, indicating growing investor interest.

Portfolio Pulse from Khyathi Dalal

February 15, 2024 | 9:07 pm

DIS

FOX

WBD

The streaming deal involving Disney, Fox, and Warner is under scrutiny by the Department of Justice (DOJ) for potential antitrust issues, as reported by Bloomberg Law. This review could impact the future operations and strategies of the companies involved in the streaming sector.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 7:16 pm

AAPL

META

SPOT

Meta Platforms Inc (NASDAQ:META) has introduced guidelines for small businesses to bypass Apple Inc's (NASDAQ:AAPL) App Store commissions by purchasing ads through a web browser. This move, aimed at avoiding Apple's up to 30% cut from in-app purchases, escalates the rivalry between the two tech giants. Apple's strict policies have been criticized by other companies as well, including Spotify Technology SA (NYSE:SPOT). Meta's ad revenue has been significantly impacted by Apple's privacy changes, with an estimated loss of $10 billion. The new ad purchasing policy will initially apply in the U.S. and expand to other regions later this year.

Portfolio Pulse from Anusuya Lahiri

February 15, 2024 | 7:06 pm

GLUE

RHHBY

Wedbush initiated coverage on Monte Rosa Therapeutics Inc (NASDAQ:GLUE) with an Outperform rating and a price target of $11, highlighting the company's AI/ML-based QuEEN platform and its lead asset, MRT-2359, for cancer and autoimmune diseases. Monte Rosa's strategic collaboration with Roche Holdings AG (OTC:RHHBY) could bring in over $2 billion in milestone payments plus royalties. GLUE shares rose 14.29% to $5.44.

Portfolio Pulse from Vandana Singh

February 15, 2024 | 7:05 pm

MSFT

OpenAI announced the development of tools aimed at detecting misleading content, including a detection classifier specifically designed to identify videos generated by Sora. This initiative is part of OpenAI's efforts to combat the spread of misinformation and enhance content authenticity. Microsoft (MSFT), a key partner and investor in OpenAI, may see implications from this development.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 6:21 pm

AMZN

AVGO

GOOG

GOOGL

META

MSFT

Meta Platforms Inc (NASDAQ:META) is expanding its board with Broadcom Inc's (NASDAQ:AVGO) CEO, Hock E. Tan, and philanthropist John Arnold, following Sheryl Sandberg's departure. This move aligns with Meta's focus on artificial general intelligence (AGI) and efficiency. The tech sector, including Amazon (NASDAQ:AMZN), Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL), Microsoft Corp (NASDAQ:MSFT), and Meta, is shifting towards cost control and efficiency, with Meta's stock rising 2.77% recently.

Portfolio Pulse from Anusuya Lahiri

February 15, 2024 | 5:26 pm